RT Journal Article
SR Electronic
T1 The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.170501
DO 10.3899/jrheum.170501
A1 Mads Ammitzbøll-Danielsen
A1 Mikkel Østergaard
A1 Esperanza Naredo
A1 Annamaria Iagnocco
A1 Ingrid Möller
A1 Maria-Antonietta D’Agostino
A1 Frédérique Gandjbakhch
A1 Lene Terslev
YR 2017
UL http://www.jrheum.org/content/early/2017/12/11/jrheum.170501.abstract
AB Objective To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean ≥ 0.8). Conclusion The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.